Daniel R. Chard - Feb 14, 2024 Form 4 Insider Report for MEDIFAST INC (MED)

Role
Chairman & CEO, Director
Signature
/s/ Jason L. Groves, attorney-in-fact
Stock symbol
MED
Transactions as of
Feb 14, 2024
Transactions value $
-$288,212
Form type
4
Date filed
2/16/2024, 05:52 PM
Previous filing
May 1, 2023
Next filing
Mar 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MED Common Stock Award $0 +16.5K +34.98% $0.00 63.6K Feb 14, 2024 Direct F1
transaction MED Common Stock Tax liability -$288K -5.47K -8.6% $52.68 58.1K Feb 14, 2024 Direct
holding MED Common Stock 109K Feb 14, 2024 The Dan and Allyson Family Irrevocable Trust F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 8,243 Performance Stock Units were granted on March 17, 2021, and vested on December 31, 2023 and converted into common stock on a two-for-one basis due to the achievement of certain performance factors. The Compensation Committee of the Medifast Board of Directors approved the performance factors on February 14, 2024 and the shares were released on February 14, 2024.
F2 These shares are directly owned by The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee.